Genentech / Seragon Pharmaceuticals Seragon Pharmaceuticals Inc. / Seragon Pharmaceuticals Inc. / Roche Group / Chugai Pharmaceutical / F. Hoffmann-La Roche Ltd / /
Country
Switzerland / Japan / United States / /
Currency
CHF / USD / / /
Event
FDA Phase / M&A / / /
IndustryTerm
biotechnology / treatment of hormone receptor-positive breast cancer / research-focused healthcare / pharmaceuticals / diabetes management / care for hormone receptor-positive breast cancer / /
MedicalCondition
tissue-based cancer / hormone receptor-positive breast cancer / breast cancer / cancers / breast cancers / disease / diabetes / infectious diseases / hormone receptor-driven cancers / /
MedicalTreatment
antibiotics / chemotherapy / /
Organization
World Health Organization / /
Person
Nicolas Dunant / Ulrike Engels-Lange / Richard Scheller / Nina Schwab-Hautzinger / Claudia Schmitt / / /
Position
leader / majority shareholder / Executive Vice President and Head / Executive Vice President and Head of Research / Head / /
Roche announces definitive agreement to acquire Seragon Pharmaceuticals